94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Ana Caroline Brambilla Falvella1
Bradley Joseph Smith1
Licia C. Silva-Costa1
Aline G. F. Valença1
Fernanda Crunfli1
Antonio W. Zuardi2
Jaime E. Hallak2
José A. Crippa2
Valéria de Almeida1*
Daniel Martins-de-Souza1,3,4,5*- 1Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil
- 2Department of Neurosciences and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
- 3Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBION) Conselho Nacional de Desenvolvimento Científico e Tecnológico, São Paulo, Brazil
- 4Experimental Medicine Research Cluster (EMRC), University of Campinas, Campinas, Brazil
- 5D'Or Institute for Research and Education (IDOR), São Paulo, Brazil
A Corrigendum on
Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13
by Falvella, A. C. B., Smith, B. J., Silva-Costa, L. C., Valença, A. G. F., Crunfli, F., Zuardi, A. W., Hallak, J. E., Crippa, J. A., Almeida, V., and Martins-de-Souza, D. (2021). Front. Mol. Neurosci. 14:673144. doi: 10.3389/fnmol.2021.673144
In the original article, information from the Data Availability statement was mistakenly omitted. The corrected Data Availability Statement is below.
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD028419.
The authors apologize for the error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: benztropine, haloperidol, clozapine, MO3.13 cell line, phytocannabinoid, proteome, schizophrenia
Citation: Falvella ACB, Smith BJ, Silva-Costa LC, Valença AGF, Crunfli F, Zuardi AW, Hallak JE, Crippa JA, Almeida V and Martins-de-Souza D (2021) Corrigendum: Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front. Mol. Neurosci. 14:814907. doi: 10.3389/fnmol.2021.814907
Received:
14 November 2021; Accepted: 15 November 2021;
Published: 30 November 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Falvella, Smith, Silva-Costa, Valença, Crunfli, Zuardi, Hallak, Crippa, Almeida and Martins-de-Souza. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Valéria de Almeida, dmFsX2Zhcm1hY0B5YWhvby5jb20uYnI=; Daniel Martins-de-Souza, ZG1zb3V6YUB1bmljYW1wLmJy